Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide for GI Toxicity Prevention in SCT
NCT02215070Phase 2Completed
- Start
- Jan 2015
- Primary completion
- Feb 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pasireotide LAR in gastrointestinal toxicity, graft-versus-host disease (GVHD). Started Jan 2015; status: completed.
02
Drugs
pasireotide LAR
03
Conditions
gastrointestinal toxicitygraft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT02215070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02215070.